Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
Several clinical trials have demonstrated that anti-IL-5(R) biologics were able to improve lung function, asthma control and chronic oral corticosteroid exposure and reduce exacerbations among eosinophilic asthmatic patients. However, a certain variability in clinical responses to anti-IL-5(R) biologics was brought to light. Our study aimed at evaluating the role of baseline sputum eosinophils in identifying super-responders to mepolizumab and benralizumab. Our study reinforces the importance to examine sputum eosinophils in patients suffering from severe asthma before starting a biologic as it is associated with the intensity of response to mepolizumab and benralizumab.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Thorax - 78(2023), 11 vom: 15. Nov., Seite 1138-1141 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gerday, Sara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
71492GE1FX |
|---|
| Anmerkungen: |
Date Completed 01.11.2023 Date Revised 14.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/thorax-2022-219781 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361556683 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361556683 | ||
| 003 | DE-627 | ||
| 005 | 20231227131530.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/thorax-2022-219781 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM361556683 | ||
| 035 | |a (NLM)37657926 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gerday, Sara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.11.2023 | ||
| 500 | |a Date Revised 14.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a Several clinical trials have demonstrated that anti-IL-5(R) biologics were able to improve lung function, asthma control and chronic oral corticosteroid exposure and reduce exacerbations among eosinophilic asthmatic patients. However, a certain variability in clinical responses to anti-IL-5(R) biologics was brought to light. Our study aimed at evaluating the role of baseline sputum eosinophils in identifying super-responders to mepolizumab and benralizumab. Our study reinforces the importance to examine sputum eosinophils in patients suffering from severe asthma before starting a biologic as it is associated with the intensity of response to mepolizumab and benralizumab | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Asthma | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a mepolizumab |2 NLM | |
| 650 | 7 | |a 90Z2UF0E52 |2 NLM | |
| 650 | 7 | |a benralizumab |2 NLM | |
| 650 | 7 | |a 71492GE1FX |2 NLM | |
| 650 | 7 | |a Interleukin-5 |2 NLM | |
| 650 | 7 | |a Receptors, Interleukin-5 |2 NLM | |
| 700 | 1 | |a Graff, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Moermans, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Guissard, Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a Paulus, Virginie |e verfasserin |4 aut | |
| 700 | 1 | |a Henket, Monique |e verfasserin |4 aut | |
| 700 | 1 | |a Louis, Renaud |e verfasserin |4 aut | |
| 700 | 1 | |a Schleich, Florence |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thorax |d 1946 |g 78(2023), 11 vom: 15. Nov., Seite 1138-1141 |w (DE-627)NLM00010387X |x 1468-3296 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2023 |g number:11 |g day:15 |g month:11 |g pages:1138-1141 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/thorax-2022-219781 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2023 |e 11 |b 15 |c 11 |h 1138-1141 | ||